Follistatin

Follistatin (FST): Basic Information

Follistatin (FST) is a research-grade, synthetic protein modeled after the naturally occurring human follistatin. This protein is found in virtually all tissues of higher animals and is expressed in two distinct forms due to an alternative gene splicing process. Its core biological activity is the modulation of proteins belonging to the TGF-$\beta$ superfamily. FST exhibits particularly potent antagonistic effects on myostatin, activin, and follicle-stimulating hormone.

Follistatin’s Biological Impact

Studies, including those conducted by Russian scientists, have shown that the myostatin protein restricts the differentiation and growth of muscle cells. Myostatin is classified within the TGF-$\beta$ protein family and is consequently susceptible to inhibition by follistatin. Prior research has demonstrated that genetic modification that reduces or eliminates myostatin in animal subjects leads to a significant gain in muscle mass. The development of exceptional strength and muscle growth in animals lacking functional myostatin underscores the critical role this protein plays in maintaining muscular balance and regulating muscle size. Myostatin is a primary functional controller of muscle development.

In mouse models, follistatin treatment has been observed to promote an increase in lean muscle tissue without any associated fat accumulation. Mice treated with follistatin experienced a 35% increase in muscle mass after a period of only seven weeks. Furthermore, genetic modifications ensuring uninterrupted follistatin expression (in the "follistatin group") created a notable contrast with the control group by preventing the age-related decline of muscle mass without the onset of adiposity (fat gain).

Current investigations exploring hair production in mice indicate that the utilization of follistatin leads to enhanced muscle development and size. This finding is relevant to the therapeutic potential of this protein in managing various muscle disorders, such as inclusion body myositis, for which no current treatment strategy exists. For example, in preclinical models of Duchenne muscular dystrophy (DMD), the introduction of follistatin resulted in a significant reduction in disease progression and severity (producing weeks of clinically relevant changes in strength). Experimental evidence suggests that follistatin can either protect existing muscle fibers or activate salvaged muscle, offering hope to individuals suffering from these currently untreatable muscle-wasting conditions.

Extended research into follistatin’s effects on muscle growth has shown that gene therapy administration of follistatin, regardless of the animal's age, can provide long-lasting benefits, including increased body mass. Delivering follistatin via a gene vector in mouse models resulted in remarkable improvements in lifespan, metabolic activity, and cardiovascular function. These advantageous effects were observed irrespective of the animal’s age at the time of gene therapy.

Data suggests that follistatin promotes muscle growth by stimulating the regeneration of muscle satellite cells. The protein may also facilitate rapid tissue repair following injury, potentially reducing recovery times. Scientists are investigating whether follistatin administration can enhance athletic performance, increase strength, or counteract sarcopenia (age-related muscle decline). Research indicates a powerful therapeutic potential for improving muscle strength and mass, with the effects understood to be predominantly skeletal muscle-mediated. Follistatin may also counteract muscle wasting or decline caused by excessive activin signaling.

Follistatin and Breast Cancer Outcome

Studies have investigated the connection between elevated follistatin concentrations and cancer prognosis using the enzyme immunoassay technique and reverse transcription polymerase chain reaction (RT-PCR) on cytosolic preparations from neoplastic tissue. The findings show that while low follistatin levels were detected in surviving tumor tissue, a strong correlation exists between higher follistatin levels and improved breast cancer survival—increased follistatin production was substantially linked to a better prognosis (lower mortality).

Follistatin’s ability to inhibit tumors is due to its blocking of activin-signal-regulated pathways. These same factors are major contributors to the intense cell proliferation associated with breast cancer development and other tumor-forming diseases. Further investigations have found that follistatin blocks signals that stimulate elevated rates of cell growth.

Research analyzing tumor growth mechanisms in both human and mouse studies demonstrated that the ratio of follistatin expression within tumor tissue, among other biomarkers, was a determining factor in survival outcomes. In cancer settings, improved patient outcomes are observed when follistatin inhibits activin and related TGF superfamily peptides.

Follistatin in Esophageal Cancer

Research indicates that the expression of follistatin and the presence of a follistatin-like agent may be involved in the transition from normal esophageal tissue to Barrett's esophagus, a precancerous condition. A study analyzed tissue samples from patients with both normal and Barrett's esophageal tissue, tracking expressions to help identify the changes that occur during the progression of Barrett's esophagus.

While the exact underlying mechanism is not fully understood, the scientists characterized multiple processes that occur sequentially as normal tissue transitions through Barrett's esophagus to the development of adenocarcinoma. These patterns suggest that the quantity of follistatin may eventually lead to adverse developments in various models.

Follistatin Research: Broad Cancer Implications

Investigations have revealed that follistatin plays important roles in various cancers, extending its effects beyond breast cancer and liver function. Follistatin has been implicated in several types of diseases, with lower concentrations detected in affected patients. Cancer studies suggest follistatin has broad applications—it improved survival in breast cancer, and other progressive diseases (including those with genetic influences) were similarly and strongly associated with outcomes. Drug candidates designed to target these disease states could potentially reduce disease severity and substantially improve survival.

Follistatin and Cell Regeneration

Experiments in rats have revealed that the expression of follistatin promotes cellular regrowth processes. Examinations following major liver surgery in rats (where 70% of the liver mass was excised) found rapid follistatin expression in hepatic cells to restore the organ. Specifically, hepatic cells produce follistatin proportionally following organ injury. This mechanism is also recognized as a way to accelerate normal growth. Elevated follistatin levels were documented to persist five days after the procedure. The observed follistatin levels correlate with faster regenerative processes for both hepatic tissue and cellular recovery.

Follistatin Research and Liver Defense

Research suggests that follistatin acts as a protective mechanism against certain forms of fibrosis and disease. Testing on mice demonstrated that follistatin led to a 75% reduction in fibrotic changes in models where liver fibrosis and disease were experimentally induced. Liver fibrosis is linked to the progression of cancer in the liver.

Follistatin Offers Insight into Congenital Blindness

Research has uncovered a connection between follistatin and the mechanism of human sight. It is established that TGF-$\beta$ signaling is essential for the proper structural development of the eye. Further research showed that follistatin controls activin signaling, a protein type that regulates bone biomechanics and architecture. Follistatin acts as an inhibitor of many proteins that regulate bone activity. Genetic testing indicates that reduced follistatin expression, as observed in certain genetic conditions, is associated with excessive bone growth that presses on the eye, leading to blindness.

Follistatin Research and Hair Growth

Follistatin’s effect on hair development varies with its anatomical location. Laboratory studies have indicated that a follistatin deficiency leads to reduced subcutaneous follicle growth. Measurements in a follistatin-free mouse model showed decreased hair follicle production. This finding is relevant to the growing interest in reversing age-related hair loss through the biologically relevant application of follistatin to restore follicular hair and cells.

Follistatin Research and Metabolic Disorders

Follistatin demonstrates benefits in metabolic dysfunction primarily through its positive influence on muscle. Muscle tissue is a major site for glucose consumption and storage. The resulting increase in muscle mass is associated with healthy trends, including a decrease in pathophysiological alterations and diminished blood glucose levels. In research utilizing diabetic rat models, the pathology and decline associated with diabetes showed improvement, likely attributable to the improved regulation of muscle strength and mass. Ongoing research is evaluating metabolic conditions and risk factors associated with follistatin.

The Future of Follistatin Research

The study of follistatin is relevant to a diverse range of human conditions, spanning from cancer and muscle dysfunction to diabetes and insulin resistance. The field is robust, with new research constantly emerging due to the protein's widely recognized capabilities. Follistatin research possesses substantial potential, including the possibility of establishing new clinical standards for a variety of deficiencies and illnesses.

The Follistatin 311 variant exhibits moderate side effects but no widespread adverse impacts. Safety data for this molecule is limited compared to other research compounds. This information is intended solely for educational and scientific research and is not for human consumption.

Article Author

The literature summarized above was organized, edited, and researched by Dr. Logan, M.D. Dr. Logan holds a B.S. in molecular biology and a doctorate from the Case Western Reserve University School of Medicine.

Scientific Journal Author

Ruth A. Keri, Ph.D., is a Professor and Vice Chair at the Department of Pharmacology at the Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center Research. Over 17 years, her research has focused on the genomic consequences of precocious puberty, endocrine therapy resistance, and the development of misdirected mouse models of breast cancer, as well as the evaluation of scientific tumors treated across all conditions. Her proficiency in cell biologic models of cancer has resulted in over 100 peer-reviewed scientific findings detailing pathways that contribute to aggressive cancer, including those involving vitamin D, autophagy, rapamycin, and taxaweb in mammary cancer models. Most notably, she has published foundational work providing a thorough understanding of hormone production by breast cancer epithelial cells and their potential resistance mechanisms, as well as a groundbreaking understanding of the cellular and population basis of endocrine therapy resistance. They have also acquired expertise in the analysis of proliferation, apoptosis, migration, and invasion, and the efficacy of standard versus novel therapeutics. Her insights into the mechanisms and genome-level expression changes that determine drug treatment effects have led to many novel discoveries. She was the co-leader of the Susan Cancer Progression Development at the Case Comprehensive Cancer Center, where she established a training program for basic scientists seeking to advance in the field. She recently received the Alumni Summit Mentor Award and the Ohio Women's Achievement Award.

Ruth A. Keri, Ph.D., is referenced as a leading scientist contributing to research on the medicinal application of follistatin. Her work on the translational applications of follistatin peptides has spanned more than a decade. The purpose of this citation is to acknowledge and credit the educational insights derived from her publications concerning the biochemical medicinal properties of the research.

Reference Bibliography

• S. Patelus, J. J. Phillips, J. Souzaiga, D. W. da Fonseca, and M. Graves. "Follistatin's regulatory influence on immune system dysfunction in diabetic human subjects with potential therapeutic applications." Biomedical Integr. Diabet. Disord., vol. 45, no. 3, pp. 267-274, Jan. 2006.
• M. Grund et al. "Excessive production of the active inhibitory module within regenerative tissue systems." Regenerative Integration., Cells., vol. 41, no. 5, pp. 445-450, May. 2006.
• M. D. Schneider et al. "TGF-$\beta$1 inhibition combined with tissue factors and bone morphogenetic protein involvement." Ortho. Biol., vol. 3, pp. 118-125, 2009.
• M. R. Ziehrer et al. "Hair restoration following combined hepatic and follistatin therapeutic intervention." Science Direct. Develop., vol. 132, no. 19, pp. 4214-4222, Oct. 2005.
• C. Zhang et al. "Identifying outcomes specifically through induced Follistatin Expression in regions of tissue necrosis." Mor. Ther., vol. 20, no. 6, pp. 1551-1557, May 2015.
• C. Schneider et al. "Restoring lean muscle mass in canine models through intramuscular administration of follistatin-based vector delivery systems." Therapeutica., vol. 6, no. 10, pp. 1274-1288, 2014.
• L. H. Seabooksrooks, M. M. Hislider, J. Brick, A. Jonas, G. Haudy, E. R. Kelpson, and J. R. Moskue. "Apoptosis suppression utilizing activinase and follistatin as therapeutic approach for muscular dystrophy." Muscle Restorve., vol. 19, no. 1, pp. 201-205, Mar. 2009.
• A. Horapeletal et al. "Myostatin and activin suppression through engineered follistatin administration resulting in muscular hypertrophy and enhanced dystrophic pathology improvement in mdx mouse models beyond baseline measurements." J. Neurol. Dis., vol. 2, no. 4, pp. 24, Apr. 2015.
• A. M. Harber et al. "Lifespan extension of skeletal muscle mass and strength through gene therapy utilizing follistatin-mediated myostatin pathway inhibition." Proc. AMB Acad. Sci., U.S.A., vol. 109, no. 34, pp. E318-E327, Mar. 2009.
• C. Sedaris et al. "IGF-1's function in follistatin-mediated muscle hypertrophy development." Am. J. Physiol. - Endocrinol. Metab., vol. 300, no. 6, pp. E1057-E1067, Aug. 2010.
• K. K. Seabert et al. "Follistatin Expression in Breast Cancer as Predictor of Invasive Characteristics and Clinically Aggressive Disease Patterns with Patient Survival Correlation." Cancer Genomics Proteomics., vol. 14, no. 1, pp. 1-8, Jan. 2017.
• D. D. Seaborne, E. T. Sebrowe, E. Johnson, F. W. Adelsonsen, K. L. Hoblar Borsh, and N. K. Karr. "Follistatin as a quantifiable supplement in prostate models utilizing NSPO tumor-expressing breast cancer cellular lines." Breast Cancer Res. ECR., vol. 15, no. 1, pp. R11-R21, 2013.
• E. Striver et al. "Differential patterns of follistatin and $\beta$-SOS expression in human breast proliferative disorders." BMC Cancer., vol. 9, p. 125, Apr. 2009.
• L. Smit, J. RECALLE, D. COMBS, L. YEL and R. G. JONES. "Clinical and Therapeutic Implementations of Follistatin in Growth-Related Disorders." Eur. J. Med. Research., vol. 14, no. 6, pp. 245-253, 2009.
• T. Geiger et al. "Clinical relevance of TGF-$\beta$ Receptor-1 Expression patterns and its associated ligands inhibins and follistatin in ovarian malignancies." Int. J. Bio. Med. Clin. Res., vol. 31, no. 6, pp. 231-239, Jan. 2011.
• H. Grist et al. "Small hepatocyte proliferation in rats necessitates follistatin expression." J. Clin. Physiol., vol. 207, no. 1, pp. E203-E750, Apr. 2006.